News
Company News: Curetis Announces Preliminary, Unaudited 2019 Condensed Combined Key Financials and Provides Business Update
— Revenue increases by 64% to EUR 2.3 million, up from 1.4 million in 2018
— More than tripled total contract order volume received year-over-year to about EUR 3.4 million 2019
— Curetis N.V. shareholders to vote on March 10, 2020 on planned business combination with OpGen, Inc.
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced preliminary. unaudited condensed combined key financials for the fiscal year 2019 and provided a business update for 2020 year-to-date.
Company News: Curetis and Quaphaco Enter into Unyvero Distribution Partnership for Vietnam
— Exclusive distribution agreement for initial term of 3 years
— Quaphaco commits to minimum purchase totaling about
EUR 1.9 million during initial term
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has entered into a distribution agreement with Quaphaco for Vietnam. Quaphaco, headquartered in Ho Chi Minh City, is a leading medical equipment supplier in Vietnam that is already working with numerous renowned global IVD manufacturers.
MdB Dr. Angela Merkel zu Gast bei Medizintechnikfirma neoplas tools GmbH
– Wahlkreisbesuch anlässlich der Grundsteinlegung des Zentrums für Life Science und Plasmatechnologie in Greifswald
– Plasmatechnologie von neoplas tools ermöglicht die Behandlung von austherapierten Wunden
neoplas tools GmbH, ein Unternehmen, das plasmamedizinische Produkte zur Behandlung von akuten und chronischen Wunden sowie erreger-bedingten Hauterkrankungen entwickelt, gab heute bekannt, dass Bundeskanzlerin Angela Merkel in ihrer Funktion als örtliche Bundestagsabgeordnete die Firma am 4. Februar 2020 im Anschluss an die Grundsteinlegung für das neue Zentrum für Life Science und Plasmatechnologie in ihrem Bundestagswahlkreis Greifswald besucht hat.
Company News: Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L
— Study by international research team published in Nature Communications
— Preclinical proof-of-concept of CDR132L established
— Inhibition of a regulatory microRNA restores cardiac function
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in Nature Communications demonstrating that its lead compound CDR132L is able to reverse heart failure in preclinical in vivo studies. The research was conducted by an international team of scientists from Austria, Germany, Hungary, and the U.K.